Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.

doi:10.1371/journal.pone.0052048

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.

PloS one - 1 Jan 2012

Yu Ming-Lung, Liu Chen-Hua, Huang Chung-Feng, Tseng Tai-Chung, Huang Jee-Fu, Dai Chia-Yen, Lin Zu-Yau, Chen Shinn-Cherng, Wang Liang-Yen, Juo Suh-Hang Hank, Chuang Wan-Long, Kao Jia-Horng

Abstract excerpt

BACKGROUND: The current stopping rule for peginterferon/ribavirin therapy in hepatitis C virus genotype-1 (HCV-1) patients is based on an early virological response (EVR, defined as >2 log(10) viral reduction at treatment week 12). We aimed to explore rapid stopping rules at week 4. METHODS: We randomly allocated 528 HCV-1 patients into training and validation sets (at a 1∶2 ratio). The interleukin-28B rs8099917...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis C

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 23284866
DOI: 10.1371/journal.pone.0052048
PMCID: PMC3528729

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.PMID 23284866Read ↗

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.Semantic proximity Read ↗

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.Semantic proximity Read ↗

Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.Semantic proximity Read ↗

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.Semantic proximity Read ↗

A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.Semantic proximity Read ↗

Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.Semantic proximity Read ↗

Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.Semantic proximity Read ↗

A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.Semantic proximity Read ↗

Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection.Semantic proximity Read ↗

Management of hepatitis C virus infection: the basics.Semantic proximity Read ↗

Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.Semantic proximity Read ↗

Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.